Evidence that Amphotericin B Mediates Reactivation of Latent Epstein-Barr Virus in Hodgkin's Lymphoma Allowing Cytotoxicity by Acyclovir
Yonsei Medical Journal
;
: 287-290, 2006.
Artigo
em Inglês
| WPRIM
| ID: wpr-51463
ABSTRACT
This brief communication focuses on aspects of a recent case report (Yonsei Med J 2005;46425-30) on a full and sustained remission of Hodgkin's lymphoma (HL) after a single day of chemotherapy. A septic episode required stopping chemotherapy and starting amphotericin B and acyclovir. Remission evidence was seen within days of starting these. A review of research supporting the notion that amphotericin B can reactivate latent Epstein-Barr virus and thus allow acyclovir to kill infected HL cells is given. Experimental work is required to confirm or refute this possibility. If successful, amphotericin B and acyclovir treatment could be extended to other EBV-driven cancers such as Burkitt's lymphoma, nasopharyngeal carcinoma and the occasional EBV-related epithelial cancer of the breast, colon, prostate, and others.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Ativação Viral
/
Indução de Remissão
/
Aciclovir
/
Doença de Hodgkin
/
Ganciclovir
/
Anfotericina B
/
Linfoma de Burkitt
/
Fator de Necrose Tumoral alfa
/
Herpesvirus Humano 4
/
Sinergismo Farmacológico
Limite:
Humanos
Idioma:
Inglês
Revista:
Yonsei Medical Journal
Ano de publicação:
2006
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS